Manish A Shah1, Lindsay A Renfro2, Carmen J Allegra2, Thierry André2, Aimery de Gramont2, Hans-Joachim Schmoll2, Daniel G Haller2, Steven R Alberts2, Greg Yothers2, Daniel J Sargent2. 1. Manish A. Shah, Weill Cornell Medical College, New York/Presbyterian Hospital, New York, NY; Lindsay A. Renfro, Steven R. Alberts, and Daniel J. Sargent, Mayo Clinic, Rochester, MN; Carmen J. Allegra, University of Florida, Gainesville, FL; Thierry André, Hôpital Saint Antoine, Paris; Aimery de Gramont, Franco-British Institute, Levallois-Perret, France; Hans-Joachim Schmoll, University Clinic Halle (Saale), Halle, Germany; Daniel G. Haller, University of Pennsylvania, Philadelphia; and Greg Yothers, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA. mas9313@med.cornell.edu. 2. Manish A. Shah, Weill Cornell Medical College, New York/Presbyterian Hospital, New York, NY; Lindsay A. Renfro, Steven R. Alberts, and Daniel J. Sargent, Mayo Clinic, Rochester, MN; Carmen J. Allegra, University of Florida, Gainesville, FL; Thierry André, Hôpital Saint Antoine, Paris; Aimery de Gramont, Franco-British Institute, Levallois-Perret, France; Hans-Joachim Schmoll, University Clinic Halle (Saale), Halle, Germany; Daniel G. Haller, University of Pennsylvania, Philadelphia; and Greg Yothers, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA.
Abstract
PURPOSE:Fluorouracil plus leucovorin (FU + LV) adjuvant chemotherapy reduced the risk of recurrence and death across all time points in a pooled analysis of 20,898 patients with colon cancer from 18 randomized studies. The impact of oxaliplatin added to FU + LV on the time course of recurrence and survival remains unknown. PATIENTS AND METHODS: A total of 12,233 patients enrolled to the randomized trials C-07, C-08, N0147, MOSAIC (Adjuvant Treatment of Colon Cancer), andXELOXA (Adjuvant XELOX) were pooled to examine the impact of oxaliplatin and tumor-specific factors on the time course of recurrence and death. For each end point, continuous-time risk was modeled over 6 years post treatment in all oxaliplatin-treated patients and patients concurrently randomized to FU + LV with or without oxaliplatin; the latter analyses supported time-dependent treatment comparisons. RESULTS: Addition of oxaliplatin significantly reduced the risk of recurrence within the first 14 months post treatment for patients with stage II disease and within the first 4 years for patients with stage III disease. Oxaliplatin also significantly reduced risk of death from 2 to 6 years post treatment for patients with stage III disease, with no differences in timing of outcomes between treatment groups (ie, oxaliplatin did not simply postpone recurrence or death compared with FU + LV alone). Patients with stage II disease receivingoxaliplatin did not exhibit a significant reduction in risk of death in the first 6 years post treatment. Recurrence risk peaked near 14 months for both treatments, and risk of recurrence and death increased with increased tumor and nodal burden. CONCLUSIONS: These analyses support the addition of oxaliplatin to fluoropyrimidine-based adjuvant therapy in patients with stage III disease and underscore the need for adequate surveillance of patients with colon cancer during the first 3 years after adjuvant therapy.
RCT Entities:
PURPOSE:Fluorouracil plus leucovorin (FU + LV) adjuvant chemotherapy reduced the risk of recurrence and death across all time points in a pooled analysis of 20,898 patients with colon cancer from 18 randomized studies. The impact of oxaliplatin added to FU + LV on the time course of recurrence and survival remains unknown. PATIENTS AND METHODS: A total of 12,233 patients enrolled to the randomized trials C-07, C-08, N0147, MOSAIC (Adjuvant Treatment of Colon Cancer), and XELOXA (Adjuvant XELOX) were pooled to examine the impact of oxaliplatin and tumor-specific factors on the time course of recurrence and death. For each end point, continuous-time risk was modeled over 6 years post treatment in all oxaliplatin-treated patients and patients concurrently randomized to FU + LV with or without oxaliplatin; the latter analyses supported time-dependent treatment comparisons. RESULTS: Addition of oxaliplatin significantly reduced the risk of recurrence within the first 14 months post treatment for patients with stage II disease and within the first 4 years for patients with stage III disease. Oxaliplatin also significantly reduced risk of death from 2 to 6 years post treatment for patients with stage III disease, with no differences in timing of outcomes between treatment groups (ie, oxaliplatin did not simply postpone recurrence or death compared with FU + LV alone). Patients with stage II disease receiving oxaliplatin did not exhibit a significant reduction in risk of death in the first 6 years post treatment. Recurrence risk peaked near 14 months for both treatments, and risk of recurrence and death increased with increased tumor and nodal burden. CONCLUSIONS: These analyses support the addition of oxaliplatin to fluoropyrimidine-based adjuvant therapy in patients with stage III disease and underscore the need for adequate surveillance of patients with colon cancer during the first 3 years after adjuvant therapy.
Authors: Steven R Alberts; Daniel J Sargent; Suresh Nair; Michelle R Mahoney; Margaret Mooney; Stephen N Thibodeau; Thomas C Smyrk; Frank A Sinicrope; Emily Chan; Sharlene Gill; Morton S Kahlenberg; Anthony F Shields; James T Quesenberry; Thomas A Webb; Gist H Farr; Barbara A Pockaj; Axel Grothey; Richard M Goldberg Journal: JAMA Date: 2012-04-04 Impact factor: 56.272
Authors: Sophie D Fosså; Ethel Gilbert; Graça M Dores; Jinbo Chen; Katherine A McGlynn; Sara Schonfeld; Hans Storm; Per Hall; Eric Holowaty; Aage Andersen; Heikki Joensuu; Michael Andersson; Magnus Kaijser; Mary Gospodarowicz; Randi Cohen; Eero Pukkala; Lois B Travis Journal: J Natl Cancer Inst Date: 2007-04-04 Impact factor: 13.506
Authors: D Sargent; Q Shi; G Yothers; E Van Cutsem; J Cassidy; L Saltz; N Wolmark; B Bot; A Grothey; M Buyse; A de Gramont Journal: Eur J Cancer Date: 2011-01-21 Impact factor: 9.162
Authors: Daniel G Haller; Josep Tabernero; Jean Maroun; Filippo de Braud; Timothy Price; Eric Van Cutsem; Mark Hill; Frank Gilberg; Karen Rittweger; Hans-Joachim Schmoll Journal: J Clin Oncol Date: 2011-03-07 Impact factor: 44.544
Authors: Carmen J Allegra; Greg Yothers; Michael J O'Connell; Saima Sharif; Nicholas J Petrelli; Linda H Colangelo; James N Atkins; Thomas E Seay; Louis Fehrenbacher; Richard M Goldberg; Seamus O'Reilly; Luis Chu; Catherine A Azar; Samia Lopa; Norman Wolmark Journal: J Clin Oncol Date: 2010-10-12 Impact factor: 44.544
Authors: J Philip Kuebler; H Samuel Wieand; Michael J O'Connell; Roy E Smith; Linda H Colangelo; Greg Yothers; Nicholas J Petrelli; Michael P Findlay; Thomas E Seay; James N Atkins; John L Zapas; J Wendall Goodwin; Louis Fehrenbacher; Ramesh K Ramanathan; Barbara A Conley; Patrick J Flynn; Gamini Soori; Lauren K Colman; Edward A Levine; Keith S Lanier; Norman Wolmark Journal: J Clin Oncol Date: 2007-04-30 Impact factor: 44.544
Authors: Daniel Sargent; Alberto Sobrero; Axel Grothey; Michael J O'Connell; Marc Buyse; Thierry Andre; Yan Zheng; Erin Green; Roberto Labianca; Chris O'Callaghan; Jean Francois Seitz; Guido Francini; Daniel Haller; Greg Yothers; Richard Goldberg; Aimery de Gramont Journal: J Clin Oncol Date: 2009-01-05 Impact factor: 44.544
Authors: John M Creasy; Kristen M Cunanan; Jayasree Chakraborty; John C McAuliffe; Joanne Chou; Mithat Gonen; Victoria S Kingham; Martin R Weiser; Vinod P Balachandran; Jeffrey A Drebin; T Peter Kingham; William R Jarnagin; Michael I D'Angelica; Richard K G Do; Amber L Simpson Journal: Ann Surg Oncol Date: 2020-09-20 Impact factor: 5.344
Authors: Natalia Kunst; Fernando Alarid-Escudero; Eline Aas; Veerle M H Coupé; Deborah Schrag; Karen M Kuntz Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-09-30 Impact factor: 4.254